LV10956B - Use of dimethylbenzofurans and dimethylbenzopyrans as 5-ht3 antagonists - Google Patents
Use of dimethylbenzofurans and dimethylbenzopyrans as 5-ht3 antagonists Download PDFInfo
- Publication number
- LV10956B LV10956B LVP-95-184A LV950184A LV10956B LV 10956 B LV10956 B LV 10956B LV 950184 A LV950184 A LV 950184A LV 10956 B LV10956 B LV 10956B
- Authority
- LV
- Latvia
- Prior art keywords
- formula
- methoxy
- enantiomers
- amino
- cis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Addiction (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Furan Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyrane Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Dental Preparations (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Claims (10)
- LV 10956 PATENTA FORMULA 1. Savienojuma ar formulutā farmaceitiski saderīga pievienotas skābes sāls formas, tā stereoķīmiska izomēra formas, kur R1 un R2 apzīmē ūdeņradi vai R1 un R2, savienoti kopā, veido divvērtīgu radikālu ar formulu -CH=CH-CH=CH- (a), -CH=C(CI)-CH=CH- (b) vai -CH=CH-C(CI)=CH- (C); n apzīmē 2, 3 vai 4; R3 apzīmē ūdeņradi vai metoksigrupu; m apzīmē 1 vai 2; R1 apzīmē ūdeņradi, aminogrupu vai C,.3alkilkarbonilaminogrupu; un R5 apzīmē ūdeņradi vai halogēnu, izmantošana medikamenta ražošanai 5-HT3-nosacīto traucējumu ārstēšanai.
- 2. Izmantošana, saskaņā ar 1. punktu, kur R3 apzīmē metoksigrupu un tam ir cis-konfigurācija.
- 3. Izmantošana, saskaņā ar 2. punktu, kur savienojums ir pa kreisi griezošs. 1 Izmantošana, saskaņā ar 1. punktu, kur savienojums ir 2 (-)-cis-4-amino-5-hlor-2,3-dihidro-Ņ-[1-[3-[(3,4-dihidro-4-okso-2-piri-midinil)amino]propil]-3-metoksi-4-piperidinil]-2,2-dimetil-7-benzofu-rānkarboksamīds vai (-)-cis-4-amino-5-hlor-Ņ-[1 -[2-[(3,4-dihidro-4--okso-2-pirimidinil)amino]etil]-2,3-dihidro-3-metoksi-4-piperidinil]--2,2-dimetil-7-benzofurānkarboksamīds, vai tā farmaceitiski saderīga pievienotas skābes sāls forma.
- 5. Savienojuma pa kreisi griezošs enantiomērs ar formuluOH 'ļļ— NH-(CHj)n-NNHvai tā farmaceitiski saderīga pievienotas skābes sāls forma, kur R1 un R2 apzīmē ūdeņradi vai R1 un R2, savienoti kopā, veido divvērtīgu radikālu ar formulu -CH=CH-CH=CH- (a), -CH=C(CI)-CH=CH- (b) vai -CH=CH-C(CI)=CH- (c); n apzīmē 2 vai 3; R3 apzīmē metoksigrupu un tam ir cis-konfigurācija; m apzīmē 1 vai 2; R4 apzīmē ūdeņradi, aminogrupu vai C^alkilkarbonilaminogrupu; un R5 apzīmē ūdeņradi vai halogēnu.
- 6. Savienojums, saskaņā ar 5. punktu, kur savienojums ir (-)-cis-4-amino-5-hlor-2,3-dihidro-Ņ-[1-[3-[(3,4-dihidro-4-okso-2-piri-midinil)amino]propil]-3-metoksi-4-pipendinil]-2,2-dimetil*7-benzofu-rānkarboksamīds vai (-)-cis-4-amino-5-hlor-Ņ-[1 -[2-[(3,4-dihidro-4-ok-so-2-pirimidinil)amino]etil]-2,3-dihidro-3-metoksi-4-piperidinil]-2,2-di- 3 LV 10956 metil-7-benzofurānkarboksamīds, vai tā farmaceitiski saderīga pievienotas skābes sāls forma.
- 7. Farmaceitisks sastāvs, kas satur inertu nesēju un kā aktīvo sastāvdaļu satur savienojuma, saskaņā ar 5. punktu, 5-HT3-antagonistiski efektīvu daudzumu.
- 8. Enantiomēri bagātināts vai enantiomēri tīrs cis-3-metoksi-4-amino-piperidins ar formulu OCHj A-N. NHj (XIX-a) vai tā farmaceitiski saderīgs pievienotas skābes sāls, kur A ir ūdeņradis, -(CHz)n-NH2, -(CH2)n-NH-P, P1 vai L, kur P un P' katrs neatkarīgi apzīmē C,.4alkilkarbonilgrupu; C^alkiloksikarbonil-grupu.; trihalogēnmetilkarbonilgrupu; difenilmetilgrupu; trifenilmetil-grupu vai arilmetilgrupu, kur arilgrupa ir fenilgrupa, neobligāti aizvietota ar līdz diviem aizvietotājiem, kas izvēlēti no C,.4alkiloksi-grupas vai halogēna; un L apzīmē radikālu ar formulukur R1 un R2 apzīmē ūdeņradi vai R' un R2, savienoti kopā, veido divvērtīgu radikālu ar formulu -CH=CH-CH=CH- (a), -CH=C(CI)-CH=CH- (b) vai -CH=CH-C(CI)=CH- (c); un n apzīmē 2, 3 vai 4.
- 9. Starpprodukts, saskaņā ar 8. punktu, kur starpprodukts ir enantiomēri bagātināts vai enantiomēri tīrs cis-3-metoksi-4-aminopiperidīns ar formulu 5 4 _ .OCHj (XIV-a), p'-\ >-nh: kur P1 ir C,.4alkilkarbonilgrupa; C,.4alkiloksikarbonilgrupa; trihalogēnmetilkarbonilgrupa; difenilmetilgrupa; trifenilmetilgrupa vai arilmetilgrupa, kur arilgrupa ir fenilgrupa, neobligāti aizvietota ar līdz diviem aizvietotājiem, kas izvēlēti no CMalkiloksigrupas vai halogēna; 10 vai tā pievienotas skābes sāls.
- 10. Metode enantiomēri bagātināta vai enantiomēri tīra cis-3-metoksi-4--aminopiperidīna ar formulu 15 och3 A-N NH2 (XIX-aj 20 kur A ir ūdeņradis, -(CH2)n-NH2, -(CH2)n-NH-P, P1 vai L, kur P un P1 katrs neatkarīgi apzīmē C,.4alkilkarbonilgrupu; C,.4alkiloksikarbonil-grupu; trihalogēnmetilkarbonilgrupu; difenilmetilgrupu; trifenilmetil-grupu vai arilmetilgrupu, kur arilgrupa ir fenilgrupa, neobligāti aizvietota ar līdz diviem aizvietotājiem, kas izvēlēti no C,.4alkiloksi-grupas vai halogēna; un L apzīmē radikālu ar formulu 2530 kur R’ un R2 apzīmē ūdeņradi vai R1 un R2, savienoti kopā, veido divvērtīgu radikālu ar formulu *CH=CH-CH=CH- (a), -CH=C(CI)-CH=CH- (b) vai -CH=CH-C(CI)=CH- (c); un n apzīmē 2, 3 vai 4, 35 5 5 LV 10956 iegūšanai, atšķirīga ar to, Ka racēmisku 3-metoksi-4-okso-piperidīnu ar formulu (XXIl-a), kur A ir, kā norādīts iepriekš, pakļauj reakcijai ar hirāla amina vienu enantiomēru ar formulu (XXIII), kur R8 ir C,.6alkilgrupa vai hidrok-siC,.6alkilgrupa un Ar ir fenilgrupa, neobligāti aizvietota ar halogēnu, C,.6alkilgrupu, Cl6alkiloksigrupu; vai naftilgrupa, neobligāti aizvietota ar halogēnu, C,.6alkilgrupu vai C^alkiloksigrupu; tā iegūst starpproduktu ar formulu (ΧΧΙ-a), kurš tiek hidrogenēts katalizatora, tāda, kā palādijs uz koka ogles, platīns uz koka ogles vai rodijs uz ogles, klātbūtnē;(XX-a) (XIX·» tā iegūst diastereomēri bagātinātu vai diastereomēri tīru starpproduktu ar formulu (XX-a) un pēc tam noņem hirālo paliggrupu Ar-CH(R8)-, un, ja vēlams, pārvērš starpproduktu ar formulu (XIX-a) pievienotas skābes sāls formā, apstrādājot ar skābi; vai pretēji, pārvērš pievienotās skābes sāli brivā bāzē ar sārmu.
- 11. Metode savienojuma ar formulu (l-a) iegūšanai, atšķirīga ar to, ka a) iegūst enantiomēri bagātinātu vai enantiomēri tīru starpproduktu ar formulu (XIX-a), kur A ir P1, pie tam minētie starpprodukti ir apzīmēti ar (XIV-a), saskaņā ar 9. punktu; 6 b) enantiomēri bagātināto vai enantiomēri tīro starpproduktu ar formulu (XIV-a) pak|auj reakcijai ar skābi ar formulu (V) vai ar tās funkcionālu atvasinājumu un pēc tam noņem aizsarggrupu P1, tā iegūstot enantiomēri tīru starpproduktu ar formulu (ll-a); 6I. Ņ-acilēšana 2. P1 noņemšana c) Ņ-alkilē enantiomēri bagātinātu vai enantiomēri tīru starpproduktu ar formulu (ll-a) ar reaģentu ar formulu (XI) un pēc tam noņem aizsarggrupu P, tā iegūstot enantiomēri bagātinātu vai enantiomēri tīru starpproduktu ar formulu (Vll-a);I.P-NH-(CHj)n-w' (XI) 2. P noņemšana d) enantiomēri bagātinātu vai enantiomēri tīru starpproduktu ar formulu (Vll-a) pak|auj reakcijai ar reaģentu ar formulu (VI), kur R6 ir ūdeņradis vai C^alkilgrupa un VV2 ir piemērota noņemamā grupa un, ja nepieciešams, atšķel aizsargājošo ētera grupu, lai iegūtu enantiomēri bagātinātu vai enantiomēri tīru savienojumu ar formulu (l-a);0-a) LV 10956 7 un, ja vēlams, tālāk tīra enantiomēri bagātinātos savienojumus ar formulu (l-a), lai iegūtu enantiomēri tīrus savienojumus ar formulu (l-a), un, ja papildus vēlams, savienojumus ar formulu (l-a) pārvērš terapeitiski aktīvā netoksiskā pievienotas skābes sāls formā, apstrādājot ar skābi; vai pretēji, pārvērš pievienotās skābes sāli brīvā bāzē ar sārmu.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97901392A | 1992-11-20 | 1992-11-20 | |
| PCT/EP1993/003206 WO1994012494A1 (en) | 1992-11-20 | 1993-11-15 | Use of dimethylbenzofurans and dimethylbenzopyrans as 5-ht3 antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| LV10956A LV10956A (lv) | 1995-12-20 |
| LV10956B true LV10956B (en) | 1996-10-20 |
Family
ID=25526607
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LVP-95-184A LV10956B (en) | 1992-11-20 | 1995-06-20 | Use of dimethylbenzofurans and dimethylbenzopyrans as 5-ht3 antagonists |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US5674868A (lv) |
| EP (1) | EP0669919B1 (lv) |
| JP (1) | JP2830952B2 (lv) |
| KR (1) | KR0166661B1 (lv) |
| AT (1) | ATE176232T1 (lv) |
| AU (1) | AU680640B2 (lv) |
| BG (1) | BG62489B1 (lv) |
| BR (1) | BR9307477A (lv) |
| CA (1) | CA2149044C (lv) |
| CZ (1) | CZ287262B6 (lv) |
| DE (1) | DE69323322T2 (lv) |
| DK (1) | DK0669919T3 (lv) |
| ES (1) | ES2129615T3 (lv) |
| FI (1) | FI952458A (lv) |
| GR (1) | GR3029831T3 (lv) |
| HU (2) | HUT72740A (lv) |
| IL (3) | IL119273A0 (lv) |
| LV (1) | LV10956B (lv) |
| MX (1) | MX9307257A (lv) |
| NO (2) | NO307690B1 (lv) |
| NZ (1) | NZ257854A (lv) |
| OA (1) | OA10158A (lv) |
| PL (1) | PL176051B1 (lv) |
| RO (1) | RO115160B1 (lv) |
| RU (1) | RU2116072C1 (lv) |
| SG (1) | SG47488A1 (lv) |
| SK (1) | SK282378B6 (lv) |
| TW (1) | TW294595B (lv) |
| UA (1) | UA49792C2 (lv) |
| WO (1) | WO1994012494A1 (lv) |
| ZA (1) | ZA938676B (lv) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5374637A (en) * | 1989-03-22 | 1994-12-20 | Janssen Pharmaceutica N.V. | N-(3-hydroxy-4-piperidinyl)(dihydrobenzofuran, dihydro-2H-benzopyran or dihydrobenzodioxin)carboxamide derivatives |
| ES2202855T3 (es) | 1997-04-18 | 2004-04-01 | Janssen Pharmaceutica Nv | Uso de antagonistas 5ht3 para promover el lavado intestinal. |
| CN1196681C (zh) * | 1997-07-11 | 2005-04-13 | 詹森药业有限公司 | (+)诺西沙必利用于制备5－ht3和5ht4 介导的疾病的药物中的用途 |
| US6239122B1 (en) * | 2000-01-05 | 2001-05-29 | Joy Ann Steele | Method of treatment of nausea, vomiting, and other disorders using estrogens |
| DE602004022819D1 (de) * | 2003-06-06 | 2009-10-08 | Vertex Pharma | Von atp-bindende kassette transportern |
| US7928104B2 (en) | 2003-11-20 | 2011-04-19 | Dominique Jean-Pierre Mabire | 7-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors |
| KR101118582B1 (ko) | 2003-11-20 | 2012-02-27 | 얀센 파마슈티카 엔.브이. | 폴리(ａｄｐ-리보스)폴리머라제 저해제로서의 6-알케닐 및6-페닐알킬 치환된 2-퀴놀리논 및 2-퀴녹살리논 |
| BRPI0512790A (pt) * | 2004-06-30 | 2008-04-08 | Janssen Pharmaceutica Nv | derivados de 2-alquil quinazolinona substituìdos como inibidores de parp |
| EA014955B1 (ru) | 2004-06-30 | 2011-04-29 | Янссен Фармацевтика Н. В. | Производные фталазина в качестве ингибиторов parp |
| CN1980913B (zh) | 2004-06-30 | 2011-12-14 | 詹森药业有限公司 | 作为parp抑制剂的喹唑啉二酮衍生物 |
| WO2008107478A1 (en) | 2007-03-08 | 2008-09-12 | Janssen Pharmaceutica Nv | Quinolinone derivatives as parp and tank inhibitors |
| WO2009053373A1 (en) | 2007-10-26 | 2009-04-30 | Janssen Pharmaceutica Nv | Quinolinone derivatives as parp inhibitors |
| EP2260026B1 (en) | 2008-03-27 | 2011-06-22 | Janssen Pharmaceutica, N.V. | Quinazolinone derivatives as tubulin polymerization inhibitors |
| WO2009118382A1 (en) | 2008-03-27 | 2009-10-01 | Janssen Pharmaceutica Nv | Tetrahydrophenanthridinones and tetrahydrocyclopentaquinolinones as parp and tubulin polymerization inhibitors |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1183847A (en) * | 1981-10-01 | 1985-03-12 | Georges Van Daele | N-(3-hydroxy-4-piperidinyl)benzamide derivatives |
| ZW12187A1 (en) * | 1986-07-03 | 1989-02-01 | Janssen Pharmaceutica Nv | 4-(aroylamino)piperidinebutanamide derivatives |
| CA1317940C (en) * | 1987-09-25 | 1993-05-18 | Georges H. P. Van Daele | Substituted n-(1-alkyl-3-hydroxy-4-piperidinyl)benzamides |
| US5374637A (en) * | 1989-03-22 | 1994-12-20 | Janssen Pharmaceutica N.V. | N-(3-hydroxy-4-piperidinyl)(dihydrobenzofuran, dihydro-2H-benzopyran or dihydrobenzodioxin)carboxamide derivatives |
| GB9005014D0 (en) * | 1990-03-06 | 1990-05-02 | Janssen Pharmaceutica Nv | N.(4.piperidinyl)(dihydrobenzofuran or dihydro.2h.benzopyran)carboxamide derivatives |
-
1993
- 1993-11-03 TW TW082109153A patent/TW294595B/zh active
- 1993-11-15 EP EP94900151A patent/EP0669919B1/en not_active Expired - Lifetime
- 1993-11-15 SG SG1996002238A patent/SG47488A1/en unknown
- 1993-11-15 ES ES94900151T patent/ES2129615T3/es not_active Expired - Lifetime
- 1993-11-15 JP JP6512708A patent/JP2830952B2/ja not_active Expired - Fee Related
- 1993-11-15 UA UA95048357A patent/UA49792C2/uk unknown
- 1993-11-15 KR KR1019950701615A patent/KR0166661B1/ko not_active IP Right Cessation
- 1993-11-15 DE DE69323322T patent/DE69323322T2/de not_active Expired - Fee Related
- 1993-11-15 SK SK675-95A patent/SK282378B6/sk unknown
- 1993-11-15 AT AT94900151T patent/ATE176232T1/de not_active IP Right Cessation
- 1993-11-15 HU HU9501476A patent/HUT72740A/hu unknown
- 1993-11-15 NZ NZ257854A patent/NZ257854A/en unknown
- 1993-11-15 RO RO95-00941A patent/RO115160B1/ro unknown
- 1993-11-15 PL PL93309045A patent/PL176051B1/pl not_active IP Right Cessation
- 1993-11-15 US US08/416,914 patent/US5674868A/en not_active Expired - Fee Related
- 1993-11-15 CA CA002149044A patent/CA2149044C/en not_active Expired - Fee Related
- 1993-11-15 RU RU95113434A patent/RU2116072C1/ru not_active IP Right Cessation
- 1993-11-15 BR BR9307477A patent/BR9307477A/pt not_active Application Discontinuation
- 1993-11-15 DK DK94900151T patent/DK0669919T3/da active
- 1993-11-15 WO PCT/EP1993/003206 patent/WO1994012494A1/en active IP Right Grant
- 1993-11-15 CZ CZ19951258A patent/CZ287262B6/cs not_active IP Right Cessation
- 1993-11-15 AU AU54659/94A patent/AU680640B2/en not_active Ceased
- 1993-11-18 IL IL11927396A patent/IL119273A0/xx unknown
- 1993-11-18 IL IL11927393A patent/IL119273A/xx not_active IP Right Cessation
- 1993-11-18 IL IL107654A patent/IL107654A/en not_active IP Right Cessation
- 1993-11-19 ZA ZA938676A patent/ZA938676B/xx unknown
- 1993-11-19 MX MX9307257A patent/MX9307257A/es unknown
-
1995
- 1995-04-20 BG BG99593A patent/BG62489B1/bg unknown
- 1995-05-19 OA OA60663A patent/OA10158A/en unknown
- 1995-05-19 NO NO951980A patent/NO307690B1/no unknown
- 1995-05-19 FI FI952458A patent/FI952458A/fi unknown
- 1995-06-20 LV LVP-95-184A patent/LV10956B/en unknown
- 1995-06-30 HU HU95P/P00699P patent/HU211546A9/hu unknown
-
1997
- 1997-05-01 US US08/848,777 patent/US5863923A/en not_active Expired - Fee Related
-
1999
- 1999-03-31 GR GR990400922T patent/GR3029831T3/el unknown
- 1999-11-24 NO NO995762A patent/NO308530B1/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8071651B2 (en) | 5-amino-4-hydroxy-7-(imidazo [1,2-A] pyridin-6-ylmethyl)-8-methyl-nonamide derivatives and related compounds as renin inhibitors for the treatment of hypertension | |
| US5322844A (en) | Alkoxy-4 (1H)-pyridone derivatives, processes for the preparation thereof, and pharmaceutical compositions containing them | |
| EP0669919B1 (en) | Use of dimethylbenzofurans and dimethylbenzopyrans as 5-ht3 antagonists | |
| JP2830936B2 (ja) | 置換ｎ−（１−アルキル−３−ヒドロキシ−４−ピペリジニル）ベンズアミド類 | |
| ZA200302801B (en) | Chimical compounds. | |
| EP1870405A1 (en) | Carbonylated (Aza)cyclohexanes as dopamine D3 receptor ligands | |
| PL168356B1 (pl) | Sposób wytwarzania nowych pochodnych N-(4-piperydynylo)-(dihydrobenzofurano lub dihydro-2H-benzopirano)karbonamidów PL PL PL PL PL PL PL | |
| EP0727421B1 (en) | Agents for improving sleep | |
| JPH0730072B2 (ja) | 置換３，４‐ジヒドロ‐２ｈ‐ベンゾピラン | |
| EP2297148B8 (fr) | NOUVEAUX DERIVES DE (PIPERAZINYL PONTE)-1-ALCANONE ET LEUR UTILISATION COMME INHIBITEURS DE p75 | |
| NZ196086A (en) | 1-phenyl-2-cyclohexene-1-alkylamine derivatives and pharmaceutical compositions | |
| FI90863B (fi) | Analogiamenetelmä ripulinvastaisten 4-(bentsoyyliamino)piperidiinibutaaniamidijohdannaisten valmistamiseksi | |
| ZA200109706B (en) | Ethanesulfonyl-piperidine derivatives. | |
| NZ297312A (en) | 1-[2-phenyl-4-(4-(3-hydroxythien-2-yl)piperidino)butanoyl]azepane derivatives | |
| IE83401B1 (en) | Agents for improving sleep |